Human liver patient-derived HUB Organoids as a promising tool to study drug-induced liver injury and drug metabolism for improved preclinical toxicology assessment

Drug toxicology studies are essential for assessing drug safety and represent a pivotal step in the preclinical stages of drug development. However, advances in drug discovery are often hampered by the lack of suitable preclinical models that recapitulate the in vivo physiology of the tissue, its gene expression, and drug metabolism. Thus, there is a compelling need for advanced in vitro preclinical models to address drug toxicity and to predict drug-induced liver injury (DILI), given that liver toxicity is one of the leading causes of drugs do not reach the market.

Download this poster to discover:

• How to assess hepatotoxicity using differentiated human liver organoids
• That differentiated liver organoids display more mature hepatocyte phenotypes compared to human stem cells- or induced pluripotent stem cells-derived models
• How to measure metabolic activity and susceptibility to hepatotoxic compounds at a large scale
• How patient-derived liver organoids are superior models for predicting long-term exposure to drug-induced liver injury as compared to other preclinical models